Validation of Six Nomograms for Predicting Non-sentinel Lymph Node Metastases in a Dutch Breast Cancer Population by Dingemans, S.A. (Siem) et al.
ORIGINAL ARTICLE – BREAST ONCOLOGY
Validation of Six Nomograms for Predicting Non-sentinel Lymph
Node Metastases in a Dutch Breast Cancer Population
Siem A. Dingemans, MD1, Peter D. de Rooij, MD1, Roos M. van der Vuurst de Vries, MD1, Leo M. Budel, MD2,
Caroline M. Contant, MD, PhD1, and Anne E. M. van der Pool, MD, PhD1
1Department of Surgery, Maasstad Hospital Rotterdam, Rotterdam, The Netherlands; 2Department of Pathology, Maasstad
Hospital Rotterdam, Rotterdam, The Netherlands
ABSTRACT
Background. The usefulness of axillary lymph node dis-
section (ALND) in patients with positive sentinel nodes
(SN) is still an ongoing debate. Several nomograms have
been developed for predicting non-sentinel lymph node
metastases (NSLNM). We validated six nomograms using
data from 10 years of breast cancer surgery in our hospital.
Methods. We retrospectively analyzed all patients with a
proven breast malignancy and a SN procedure between
2001 and 2011 in our hospital.
Results. Data from 1084 patients were reviewed; 260
(24 %) had a positive SN. No patients with isolated tumor
cells, 6 patients (8 %) with micrometastases, and 65
patients (41 %) with macrometastases had additional axil-
lary NSLNM. In 2 patients (3 %) with micrometastases, the
ALND influenced postoperative treatment. In the group of
patients with macrometastases tumor size [2 cm, extran-
odal growth and having no negative SNs were predictors of
NSLNM. The revised MD Anderson Cancer Center and
Helsinki nomograms performed the best, with an area
under the curve value of 0.78.
Conclusions. ALND could probably be safely omitted in
most patients with micrometastases but is still indicated in
patients with macrometastases, especially in patients with
tumor size [2 cm, extranodal growth, and no negative
SNs. The revised MD Anderson Cancer Center and Hel-
sinki nomograms were the most predictive in our patient
group.
In the Netherlands, women have an approximate 15 %
lifetime risk of developing a breast malignancy.1 In 2013, a
total of 14,000 new patients were diagnosed with invasive
breast cancer.2 With a mortality of 3.8 % and substantial
morbidity, it is responsible for a great burden to society.1
In the management of patients with invasive breast cancer,
axillary lymph node status is an important determinant of
prognosis. For nodal staging, axillary lymph node dissection
(ALND) has, over time, been replaced by sentinel lymph
node (SLN) biopsy (SLNB).3 Between 62 and 75 % of all
patients will have a negative SLNB, and no further axillary
treatment is indicated because it offers no advantage in sur-
vival.3–7 However, in patients with a positive sentinel node
(SN), ALND has been the standard treatment until recent
times. In case of isolated tumor cells in the SN, it is dispro-
portional to perform an ALND.8 In cases of micro- and
macrometastases in the SN, it is an ongoing discussion. It
seems that in most patients, ALND is merely helpful in
staging, rather than a treatment itself. Morbidity such as
paresthesia in the forearm and axilla, persistent lymphedema,
and operated arm weakness due to ALND could be avoided in
a selected group of patients.3 Recent literature has showed that
in patients with early breast cancer and limited SN involve-
ment, ALND is not useful in gaining survival.3,9–11 For
example, the American College of Surgeons Oncology Group
Z0011 trial showed that among patients with limited SN
metastatic breast cancer treated with breast conservation and
systemic therapy, the use of SLNB alone compared to ALND
did not result in inferior survival.3
ALND can be omitted in most patients if physicians are
able to predict the axillary lymph node status by other
means. Several nomograms have been developed for pre-
dicting non-sentinel lymph node metastases (NSLNM). The
most widely validated nomograms12 are from Memorial
Sloan Kettering Cancer Center (MSKCC), MD Anderson
Cancer Center (MDA), the Mayo Clinics (Mayo), Tenon
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Hospital (Tenon), Cambridge Cancer Research, Stanford
Cancer Center, and Helsinki University Central Hospi-
tal.4,7,13–17 The nomogram from MDA has recently been
updated (MDA2).18
In this study, we retrospectively analyzed all patients in
our hospital with SLNB-positive breast cancer to determine
clinicopathologic factors that might help predict the
involvement of NSLNM. Furthermore, we tried to validate
the nomograms mentioned above.
MATERIALS AND METHODS
Eligible patients were those who underwent breast sur-
gery between January 2001 and December 2011 in our
hospital. Only patients with a proven malignancy and those
who underwent a SLNB were included. We retrospectively
reviewed patient charts. Patients with neoadjuvant
chemotherapy were excluded, as were patients with a
(synchronous) tumor of another origin. The following
characteristics were noted: type of tumor; tumor size; mul-
tifocality; Bloom–Richardson grade; estrogen receptor,
progesterone receptor, and HER2/neu status; lymphovascu-
lar invasion; number of negative and positive SNs collected;
isolated tumor cells (\0.2 mm); micrometastases ([0.2 to
B2 mm) or macrometastases ([2 mm) in the SN; extranodal
growth; whether or not a complete ALND was performed;
and the number of additional NSLNM in the ALND.
All patients underwent SLNB after injection of tech-
netium-99 m 1 cm caudal to the areola. After induction,
blue dye was injected intradermally 1 cm lateral to the
areola; this combination is an accurate method of locating
SNs.19 SNs were intraoperatively routinely analyzed by
frozen section and postoperatively by hematoxylin and
eosin staining and immunohistochemistry. The 7th edition
tumor, node, metastasis classification system from the
International Union against Cancer was used to stage the
tumors.20 When patients had [3 positive NSLNM, they
automatically received axillary radiotherapy.
Nomograms
As noted above, the MSKCC, MDA, Mayo, Tenon,
Cambridge, Stanford, and Helsinki nomograms are the most
validated.17,21 We excluded the Cambridge and Mayo
nomograms in our study because these nomograms require
size of SLN metastases as a continuous variable. Unfortu-
nately, these data were not available for a large group of
patients in our study. All patients with a positive SLNB were
evaluated in the four remaining nomograms as well as in the
MDA2 nomogram. An online calculator was used for the
MSKCC and MDA2 nomogram; the Stanford, Tenon, first
MDA, and Helsinki nomograms were calculated by hand.
Statistical Analysis
Categorical data are presented as percentage frequen-
cies. Associations between the presence of NSLNM in
ALND and the characteristics of our study group were
analyzed by the v2 test. Significance levels are derived
from two-tailed tests and were set at p\ 0.05. Multivariate
analysis was performed using a logistical regression model
to identify those risk factors independently associated with
NSLNM that had been statistically significant in the uni-
variate analysis. The mean predicted probability of
NSLNM from the five nomograms was compared to our
study group. Discrimination of the nomograms was asses-
sed by calculating the area under the curve (AUC) of the
receiver operating characteristic curve. It is widely accep-
ted that AUC values between 0.7 and 0.8 represent
considerable discrimination.22 Statistical analysis was
performed by SPSS 20 (IBM, Armonk, NY).
RESULTS
A total of 1084 patients were eligible. Demographics of
the study group are shown in Table 1. Of all patients, 260
(24 %) had a positive SN. Table 2 shows the percentages of
isolated tumor cells, micrometastases and macrometastases,
and percentages of ALND and NSLNM. Twenty-three
patients (9 %) with a positive SN did not receive an ALND
because of old age, short life expectancy, or isolated tumor
cells in the SLNB results. In two patients (3 %) with
micrometastases and NSLNM in the ALND, stage migration
occurred. They received adjuvant axillary radiotherapy.
In the micrometastases group, univariate analysis was
performed; no significant predictors of NSLNM were
found. In the univariate analysis of the patients with
macrometastases (n = 158), statistically significant pre-
dictors of NSLNM were: age\50 years (p = 0.03), tumor
size [2 cm (p = 0.003), lymphovascular invasion
(p = 0.02), extranodal growth (p = 0.009), and having no
negative SNs (p = 0.006, Table 3). In the multivariate
analysis, tumor size of [2 cm, extranodal growth, and
having no negative SNs remained statistically significant
(Table 4). The AUC values for the MSKCC, MDA, Tenon,
Stanford, Helsinki, and MDA2 nomograms were 0.72,
0.73, 0.76, 0.62, 0.78, and 0.78, respectively (Fig. 1).
DISCUSSION
This study found that ALND will change postoperative
treatment only in 3 % of patients with micrometastases,
and that in patients with macrometastases, tumor size
[2 cm, extranodal growth, and nonnegative SNs are pre-
dictors of NSLNM.
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Recently the treatment of breast cancer has greatly
changed. Whereas in the past standard treatment consisted
of a radical mastectomy including an ALND, improved
insights in cancer biology have resulted in less radical
treatment.
By performing a SLNB, a large group of patients can be
spared the adverse effects of ALND without lower survival
TABLE 1 Patient demographics
Characteristic Value (n = 1084)
Age (years), median (range) 60 (26–92)
Tumor size
Median (range) (mm) 17 (1–150)
B20 mm 717 (66 %)
[20 mm 346 (32 %)
Not available 21 (2 %)
T stage
pT1 604 (56 %)
pT2 359 (33 %)
pT3 28 (2 %)
pT4 11 (1 %)
pTis 82 (8 %)
Histomorphology
Ductal carcinoma 859 (79 %)
Lobular carcinoma 99 (9 %)
Mixed type 6 (1 %)
Other 120 (11 %)
Bloom–Richardson grade
Well differentiated 114 (11 %)
Moderately differentiated 570 (53 %)
Poorly differentiated 295 (27 %)
Not available 105 (9 %)
Estrogen receptor
Positive 806 (74 %)
Negative 221 (20 %)
Not available 57 (6 %)
Progesterone receptor
Positive 534 (49 %)
Negative 354 (33 %)
Not available 196 (18 %)
HER2/neu receptor
Positive 162 (15 %)
Negative 605 (56 %)
Not available 317 (29 %)
Multifocality
Yes 113 (10 %)
No 971 (90 %)
TABLE 2 Size of sentinel node metastases
Characteristic n (%) ALND NSLNM
Isolated tumor cells 17 (7 %) 2 (12 %) 0 (0 %)
Micrometastases 83 (34 %) 77 (93 %) 6 (8 %)
Macrometastases 160 (62 %) 158 (99 %) 65 (41 %)
ALND axillary lymph node dissection, NSLNM non-sentinel lymph
node metastases
TABLE 3 Univariate analysis of predictors of NSLNM in patients
with macrometastases
Characteristic NSLNM p (2-tailed)
No
(n = 65)
Yes
(n = 93)
Age 0.03
B50 years 25 28
[50 years 68 37
Multifocality 0.06
No 80 48
Yes 13 17
Tumor size 0.003
B2 cm 38 12
[2 cm 55 53
Bloom–Richardson score 0.21
Well differentiated 13 4
Moderately differentiated 44 32
Poorly differentiated 31 28
Estrogen receptor 0.45
Negative 17 15
Positive 75 49
Progesterone receptor 0.35
Negative 28 22
Positive 52 29
HER2/neu receptor 0.06
Negative 58 34
Positive 13 17
Lymphovascular invasion 0.02
No 86 52
Yes 7 13
Extranodal growth 0.009
No 76 41
Yes 17 24
No. of positive sentinel
node collected
0.07
1 76 45
[1 17 20
No. of negative sentinel
node collected
0.002
0 58 55
C1 35 10
NSLNM non-sentinel lymph node metastases
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rates.18 Currently, the standard treatment in our region for a
patient with a positive SLNB, except for isolated tumor
cells, is ALND. In 70 % of the patients with a positive
SLNB in our study population, an ALND was performed in
the absence of NSLNM, which is comparable to the 60–
80 % described in literature.18 This is a serious matter, as
these patients can experience significant adverse effects
such as paresthesia, weakness of the treated arm, and
lymphedema.3,10,11,23 Because of the comorbidities asso-
ciated with ALND, it is always subject to discussion and its
indication constantly revised and narrowed.
Our data support the current practice of not performing
ALND in case of isolated tumor cells, as we did not find
any NSLNM in patients with isolated tumor cells in the SN.
Performing ALND in all patients with micrometastases
is currently under debate as well. There is an increasing
amount of evidence suggesting that limited disease in non-
sentinel lymph nodes has no effect on survival.9,11 The
AATRM investigators showed in a randomized trial that in
early breast cancer patients with micrometastases, SLNB
alone was comparable to ALND in terms of locoregional
control and distant disease. This practice had no significant
effect on survival.9 The results of the IBCSG trial showed
that there was no difference in survival between patients
who did receive an ALND versus no axillary treatment
when micrometastases were found in the SN. The authors
of that trial advocated that ALND did not result in
improved local control. Favorable long-term treatment
events were significantly lower in the nonsurgical group.
Additionally, there was no difference in the two groups
receiving any type of adjuvant therapy.11 However, they
only included patients with a clinically negative axilla,
which should be taken into account when interpreting their
results. Tvedskov et al., however, advocated that ALND
should not be omitted in every patient with micrometas-
tases, as they identified a subgroup of patients who have an
increased risk of NSLNM and thus would benefit from
ALND.23 Our results support both views; most of our
patients (97 %) with micrometastases did not benefit from
ALND, supporting the contemporary approach of omitting
ALND in this patient group. However, 2 patients (3 %) did
receive additional axillary radiotherapy; this was decided
because of the number of NSLNM in the axilla.
One could opt to administer radiotherapy or routine
follow-up with ultrasound to the axilla in case of
micrometastases in the SLN instead of an ALND. In this
way, all these patients can be spared the morbidity of an
ALND. Chemotherapy and/or hormone therapy can be
sufficient to eliminate remaining disease in patients with a
low axillary tumor load, as suggested by the AATRM
investigators.9
In patients with macrometastases[2 cm in size, extra-
nodal growth and having no negative SNs proved to be
predictors of NSLNM in our patient group. Although in
most patients with macrometastases an ALND is indicated,
more authors are now advocating a more conservative
approach in this patient group as well; the Z0011 trial
showed that in selected patients with T1 or T2 breast
cancer and a positive SN, ALND might safely be omitted.3
All patients from the Z0011 trial, however, received whole
breast irradiation, which is not a common practice in every
center and thus should be taken in account. Additionally
the Dutch AMAROS trial compared ALND to radiotherapy
in T1–2 patients with a positive SLNB finding. They found
similar results in terms of axillary control between the two
treatments. The patients treated with ALND, however,
experienced significantly more morbidities compared to
patients treated with radiotherapy.10 We support the idea of
narrowing the indication for ALND in patients with
macrometastases as well. However, on the basis of our
findings, we advocate a cautious strategy when dealing
with a tumor [2 cm and/or extranodal growth and/or
having no negative SNs.
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TABLE 4 Multivariate analysis of predictors of non-sentinel lymph
node metastases in patients with macrometastases
Factor p (2-tailed)
Tumor size
B2 cm 1
[2 cm 2.6 (1.2–6.0) p = 0.02
Extranodal growth
No 1
Yes 2.4 (1.1–5.4) p = 0.03
No. of negative sentinel nodes
0 1
C1 0.3 (0.1–0.7) p = 0.006
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In our patient group, the MDA2 and Helsinki nomo-
grams performed the best, with an AUC of 0.78. Compared
to the earlier available nomogram from MDA, they added
type of tumor, proportion of positive SN findings and
extranodal growth. This resulted in an increase of 0.05 in
the AUC (0.73–0.78). To our knowledge, this is only the
second study to perform external validation of the revised
MDA nomogram. This nomogram is available as an online
calculator (http://www.mdanderson.org/), which is useful
in common practice, and it might help determine treatment
options in patients with a positive SLNB. Furthermore, the
Helsinki nomogram performed equally well, with an AUC
of 0.78. This nomogram is also user friendly: it is available
in a free Excel form in which patient characteristics can be
filled in. This nomogram might also be of use in decision
making for SLNB-positive patients.
CONCLUSIONS
In 6 patients (8 %) with micrometastases, NSLNM were
found. In only 2 patients (3 %) did it have an impact on
adjuvant treatment to the axilla. In patients with
macrometastases, tumor size of[2 cm, extranodal growth,
and having no negative SNs are predictors of NSLNM. The
Helsinki and MDA2 nomograms proved to be the most
predictive in our study group and are both easily usable.
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